AI Summary
Low-dose carvedilol is safe but ineffective in preventing heart failure in childhood cancer survivors exposed to anthracycline.
Low-dose carvedilol appears to be safe in long-term childhood cancer survivors at risk for heart failure, but did not result in significant improvement of LVWT/Dz compared with placebo. These results do not support the use of carvedilol for secondary heart failure prevention in anthracycline-exposed childhood cancer survivors.